US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings

0.9922

-0.0178-1.76%

Post-market: 0.9775-0.0147-1.48%19:48 EDT

Volume:283.25K

Turnover:279.88K

Market Cap:182.46M

PE:-14.17

High:1.01

Open:0.9984

Low:0.9717

Close:1.01

Loading ...

Overview Company News Filings

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

THOMSON REUTERS

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Press Release: Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio Teams Up With Microsoft to Develop Treatments for Human Papilloma Virus

MT Newswires Live

Tevogen leverages Microsoft partnership to deliver target identification for HPV

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (Hpv), Advancing Tvgn 920

THOMSON REUTERS

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI Into Preclinical Processes, Accelerating Drug Development and Reducing Costs

THOMSON REUTERS

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio Regains Nasdaq Compliance

MT Newswires Live

Tevogen regains compliance with Nasdaq

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

THOMSON REUTERS

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

BRIEF-Tevogen Bio Signs LOI With Cd8 Technology To Build $50 Million R&D And Manufacturing Facility

Tevogen Bio Signs Letter of Intent With CD8 Technology for R&D, Manufacturing Facility

MT Newswires Live

Tevogen Bio Signs Letter of Intent With Cd8 Technology to Build up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TVGN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":0.9922,"timestamp":1745611200000,"preClose":1.01,"halted":0,"volume":283248,"hourTrading":{"tag":"盘后","latestPrice":0.9775,"preClose":0.9922,"latestTime":"19:48 EDT","volume":4270,"amount":4225.3759,"timestamp":1745624890261},"delay":0,"floatShares":22757419,"shares":183893433,"eps":-0.070045,"marketStatus":"Market Closed","change":-0.0178,"latestTime":"04-25 16:00:00 EDT","open":0.9984,"high":1.0053,"low":0.9717,"amount":279879.54113952,"amplitude":0.033267,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.070045,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.01,"preHourTrading":{"tag":"盘前","latestPrice":0.9997,"preClose":1.01,"latestTime":"09:29 EDT","volume":8173,"amount":8237.4808835,"timestamp":1745587770614},"postHourTrading":{"tag":"盘后","latestPrice":0.9775,"preClose":0.9922,"latestTime":"19:48 EDT","volume":4270,"amount":4225.3759,"timestamp":1745624890261},"volumeRatio":0.8628464969096111},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","floatShares":22757419,"roa":"-746.67%","roe":"--","lyrEps":-0.070045,"volumeRatio":0.8628464969096111,"shares":183893433,"dividePrice":0,"high":1.0053,"amplitude":0.033267,"preClose":1.01,"low":0.9717,"week52Low":0.2556,"pbRate":"-11.79","week52High":3.09,"institutionHeld":0,"latestPrice":0.9922,"eps":-0.070045,"divideRate":0,"volume":283248,"delay":0,"ttmEps":-0.070045,"open":0.9984,"prevYearClose":1.03,"prevWeekClose":0.9796,"prevMonthClose":1.08,"prevQuarterClose":1.08,"fiveDayClose":0.9796,"twentyDayClose":1.2,"sixtyDayClose":1.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2482645853","title":"Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482645853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482645853?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:36","pubTimestamp":1731098208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA5FVRKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2482458288","title":"Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482458288","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482458288?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:36","pubTimestamp":1731098160,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 08, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen.In tandem with this announcement, Tevogen Bio reaffirms its existing agreement which provides access to a $36 million line of credit to ensure ongoing operations and fuel future growth.Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to susta","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-nears-finalization-agreement-203600118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":1},{"id":"2481165411","title":"Press Release: Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability","url":"https://stock-news.laohu8.com/highlight/detail?id=2481165411","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481165411?lang=en_us&edition=fundamental","pubTime":"2024-11-06 05:43","pubTimestamp":1730842980,"startTime":"0","endTime":"0","summary":"Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability. -- Tevogen Bio is a fully functional biotech, with investor-valued assets. over $10 billion achieved with under $40 million in spending.-- Approximately 78% of Tevogen Bio's common stock is held by company. WARREN, N.J., Nov. 05, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce that its Founder and CEO, Dr. Ryan Saadi, MD, MPH, has been recognized by ROI-NJ as an Influencer in the Health Care sector. This acknowledgment highlights Tevogen Bio's commitment to delivering advanced immunotherapies at a commercially viable and economically sustainable price.Tevogen is driven by a team of experienced industry leaders and scientists with drug develop","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":1},{"id":"2481689790","title":"Tevogen Bio Teams Up With Microsoft to Develop Treatments for Human Papilloma Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2481689790","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481689790?lang=en_us&edition=fundamental","pubTime":"2024-11-05 23:45","pubTimestamp":1730821522,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings  said Tuesday it's artificial intelligence initiative Tevogen.AI has launched a partnership with Microsoft  to investigate potential treatments for human papilloma virus.Tevogen said it has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T-cell targets to choose for a trial for TVGN 920, which will be its first oncology product.\"By leveraging Microsoft's cutting-edge AI and cloud technologies, we're able to accelerate our target identification and pre-clinical processes in ways that weren't previously possible,\" said Tevogen.AI Chief Information Officer and Head Mittul Mehta.Financial details about the project weren't provided.Price: 1.91, Change: -0.05, Percent Change: -2.81","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE000KEQY171.SGD","IE00BFSS8Q28.SGD","IE00BKPKM429.USD","BK4548","GB00B4LPDJ14.GBP","IE00B775SV38.USD","IE0004445239.USD","GB00B4QBRK32.GBP","IE00B775H168.HKD","BK4587","IE00BK4W5L77.USD","IE000W1ABFV2.USD","BK4550","IE00B5TLWC47.USD","IE00BFXG0V08.USD","IE00BKDWB100.SGD","IE00BJTD4V19.USD","BK4525","BK4585","IE00B3SWFQ91.USD","IE00BJLML261.HKD","BK4504","IE00BDCRKT87.USD","IE0004445015.USD","BK4567","IE0004086264.USD","BK4534","IE00BJJMRX11.SGD","BK4503","BK4535","IE00BJTD4N35.SGD","IE0004091025.USD","BK4566","IE00BHPRN162.USD","IE00B4YYXB79.USD","BK4538","BK4139","IE00BLSP4239.USD","IE00BJJMRY28.SGD","IE00BBT3K403.USD","TVGN","BK4592","BK4097","BK4533","IE00B3S45H60.SGD","MSFT","IE00BKVL7J92.USD","BK4528","BK4576","BK4577"],"gpt_icon":1},{"id":"2481074500","title":"Tevogen leverages Microsoft partnership to deliver target identification for HPV","url":"https://stock-news.laohu8.com/highlight/detail?id=2481074500","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481074500?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:35","pubTimestamp":1730817328,"startTime":"0","endTime":"0","summary":"Tevogen Bio (TVGN) announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (MSFT) (MSFR) Using Microsoft’s suite of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-leverages-microsoft-partnership-to-deliver-target-identification-for-hpv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-leverages-microsoft-partnership-to-deliver-target-identification-for-hpv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GB00BDT5M118.USD","IE00BFSS8Q28.SGD","BK4554","IE0009356076.USD","BK4576","BK4533","IE00BJJMRX11.SGD","IE00B4JS1V06.HKD","IE00BK4W5L77.USD","BK4139","BK4587","IE0004086264.USD","BK4548","IE00B19Z8W00.USD","BK4588","IE00B1BXHZ80.USD","IE00B775SV38.USD","TVGN","IE00BBT3K403.USD","IE00BJTD4V19.USD","IE000YTNTUN2.SGD","IE0034235295.USD","BK4579","BK4585","IE00B5949003.HKD","BK4538","IE00BDRTCR15.USD","IE00BFXG0V08.USD","IE0034235188.USD","IE00BK4W5M84.HKD","IE00BJTD4N35.SGD","IE00BKVL7J92.USD","IE00B19Z8X17.USD","IE00BLSP4239.USD","MSFT","BK4532","BK4567","IE00BKDWB100.SGD","IE000KEQY171.SGD","IE0009G5SDU7.USD","BK4534","BK4528","BK4577","IE000W1ABFV2.USD","IE0003U64NQ7.SGD","IE00BJLML261.HKD","BK4527","IE00B7KXQ091.USD","IE000ITXATA3.USD","IE0005OL40V9.USD"],"gpt_icon":0},{"id":"2481507727","title":"Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (Hpv), Advancing Tvgn 920","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507727?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:27","pubTimestamp":1730816868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA2RMS6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B1XK9C88.USD","BK4579","IE000W1ABFV2.USD","IE00BHPRN162.USD","BK4503","BK4567","IE00B3S45H60.SGD","BK4525","IE00BJJMRX11.SGD","IE00BK4W5M84.HKD","BK4592","BK4516","BK4527","IE0004091025.USD","IE00B19Z8X17.USD","IE00B4YYXB79.USD","IE00BKDWB100.SGD","BK4097","BK4588","MSFT","IE0004086264.USD","IE00B19Z9505.USD","BK4532","IE0005OL40V9.USD","BK4504","IE0004445015.USD","IE0009356076.USD","BK4538","IE000ITXATA3.USD","IE00B5TLWC47.USD","IE00BBT3K403.USD","IE00BFSS7M15.SGD","IE0034235295.USD","BK4585","GB00BDT5M118.USD","BK4533","IE0004445239.USD","IE00BJTD4V19.USD","IE00B1BXHZ80.USD","IE00B3SWFQ91.USD","IE00B5949003.HKD","BK4139","BK4577","IE00BK4W5L77.USD","IE00BKPKM429.USD","IE00BJJMRY28.SGD","BK4528","BK4535","TVGN","TVGNW"],"gpt_icon":0},{"id":"2481500849","title":"Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920","url":"https://stock-news.laohu8.com/highlight/detail?id=2481500849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481500849?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:27","pubTimestamp":1730816820,"startTime":"0","endTime":"0","summary":"Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.Tevogen Bio created a data set containing known proteins in the HPV genome to identify targe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2975016/0/en/Tevogen-Bio-Leverages-Microsoft-Partnership-to-Deliver-Machine-Learning-Based-Target-Identification-to-Address-Human-Papilloma-Virus-HPV-Advancing-TVGN-920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","IE00B19Z9505.USD","BK4528","IE0004086264.USD","BK4139","BK4525","IE0003U64NQ7.SGD","IE0005OL40V9.USD","IE0004445015.USD","IE00BJTD4N35.SGD","IE00BHPRN162.USD","BK4577","TVGN","BK4566","IE0004445239.USD","IE00BJLML261.HKD","BK4550","IE00B4JS1V06.HKD","BK4535","GB00B4LPDJ14.GBP","IE00BK4W5L77.USD","BK4538","BK4516","BK4533","IE00B5TLWC47.USD","IE00BJJMRX11.SGD","IE000ITXATA3.USD","IE0009356076.USD","IE00BJJMRY28.SGD","IE00B19Z8W00.USD","IE00BJTD4V19.USD","IE00B5949003.HKD","BK4585","IE00B1BXHZ80.USD","IE00BLSP4239.USD","MSFT","BK4567","IE00BK4W5M84.HKD","IE0034235295.USD","IE00BDCRKT87.USD","IE00B1XK9C88.USD","BK4527","IE00BKVL7J92.USD","IE000KEQY171.SGD","BK4576","IE000YTNTUN2.SGD","IE000W1ABFV2.USD","IE00B775SV38.USD","BK4504","GB00BDT5M118.USD"],"gpt_icon":1},{"id":"2481552305","title":"Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2481552305","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481552305?lang=en_us&edition=fundamental","pubTime":"2024-11-05 03:36","pubTimestamp":1730748960,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 04, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce the appointment of Anthony Tarantino as its new Patient Advocate. Tarantino, a well-known leader in firefighter safety and community advocacy, brings extensive experience in representing and supporting high-risk groups, including first responders.Anthony Tarantino previously served as President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters Association of New Jersey . In these roles, Tarantino was instrumental in advancing policies for firefighter health, safety, and wellness. One of his notable achievements was in advocating for and securing the passage of legislation in New Jersey mandating regular cancer screenings for firefighters. This legislation acknowledges the increased risk of cancer among firefighter","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-appointment-anthony-193600845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":1},{"id":"2479003147","title":"Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI Into Preclinical Processes, Accelerating Drug Development and Reducing Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2479003147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479003147?lang=en_us&edition=fundamental","pubTime":"2024-10-31 22:54","pubTimestamp":1730386496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA2RZSR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","IE00B4JS1V06.HKD","IE00B3S45H60.SGD","GB00B4LPDJ14.GBP","IE0034235303.USD","BK4585","IE000KEQY171.SGD","BK4577","BK4587","IE00B19Z8X17.USD","IE0009G5SDU7.USD","IE00BK4W5M84.HKD","IE00B19Z9505.USD","BK4548","TVGNW","IE000W1ABFV2.USD","IE00B7KXQ091.USD","BK4527","TVGN","BK4516","BK4504","IE0003U64NQ7.SGD","IE000YTNTUN2.SGD","IE00BKDWB100.SGD","MSFT","IE00B3SWFQ91.USD","BK4532","IE00B5TLWC47.USD","GB00B4QBRK32.GBP","IE0004445239.USD","IE00BLSP4239.USD","GB00BDT5M118.USD","IE000ITXATA3.USD","IE00BKPKM429.USD","IE00BJTD4N35.SGD","IE0004091025.USD","BK4097","BK4550","BK4538","BK4588","BK4581","IE0004445015.USD","BK4139","IE00BJJMRY28.SGD","BK4592","IE00B5949003.HKD","BK4567","IE0034235295.USD","BK4503","IE00BFSS7M15.SGD"],"gpt_icon":0},{"id":"2479103106","title":"Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2479103106","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479103106?lang=en_us&edition=fundamental","pubTime":"2024-10-31 22:54","pubTimestamp":1730386440,"startTime":"0","endTime":"0","summary":"Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogen’s approach has the potential to shorten timelines and substantially reduce costs. Tevogen’s AI initia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/31/2972804/0/en/Tevogen-Bio-Expands-on-Microsoft-Partnership-to-Integrate-Machine-Learning-and-AI-into-Preclinical-Processes-Accelerating-Drug-Development-and-Reducing-Costs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSFT","TVGN"],"gpt_icon":1},{"id":"2479593732","title":"Tevogen Bio Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2479593732","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479593732?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:55","pubTimestamp":1730231756,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings  said Tuesday that it has received a notification from Nasdaq that it has regained compliance with the exchange's minimum bid price requirement for continued listing.The company's shares traded above the $1 minimum price requirement for 10 consecutive trading days between Oct. 14 and Oct. 25, Tevogen added.Shares of Tevogen Bio were down 5.3% in recent trading.Price: 2.60, Change: -0.15, Percent Change: -5.29","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2210150020.SGD","TVGN","BK4112","BK4588",".IXIC","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","NQmain","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2479256107","title":"Tevogen regains compliance with Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2479256107","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479256107?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:35","pubTimestamp":1730230512,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced that it received written notice from the Listing Qualifications Staff of Nasdaq stating that the company has regained comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-regains-compliance-with-nasdaq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-regains-compliance-with-nasdaq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","IE00BKPKM429.USD","TQQQ","IE00BGHQF748.EUR","QID","LU2210150020.SGD","BK4588","SQQQ","IE00B3QW5Z07.USD","BK4585","NQmain","LU2095319765.USD","NDAQ","BK4112","MNQmain","QLD",".IXIC","BK4139","TVGN","LU2210149790.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2479255297","title":"Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2479255297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479255297?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:28","pubTimestamp":1730230112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA9ZHDCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4504","BK4532","IE0009G5SDU7.USD","IE00BDRTCR15.USD","IE00BFSS8Q28.SGD","IE00BJJMRY28.SGD","IE000YTNTUN2.SGD","IE00BKVL7J92.USD","IE00BK4W5M84.HKD","BK4592","LU2095319765.USD","IE00B7KXQ091.USD","IE0003U64NQ7.SGD","IE0034235188.USD","IE0009356076.USD","MSFT","IE00B3SWFQ91.USD","NDAQ","TVGN","IE00B1BXHZ80.USD","IE000ITXATA3.USD","IE00B4JS1V06.HKD","IE00B19Z8X17.USD","LU2210149790.SGD","BK4503","IE00BDCRKT87.USD","BK4548","IE0034235303.USD","BK4516","BK4527","TVGNW","IE000KEQY171.SGD","IE00B775SV38.USD","IE00BJTD4N35.SGD","LU2210150020.SGD","BK4554","IE00B19Z9505.USD","IE0034235295.USD","BK4525","BK4112","IE00BFSS7M15.SGD","IE00BJLML261.HKD","IE0004445239.USD","IE00BFXG0V08.USD","IE00BK4W5L77.USD","BK4528","IE00BJTD4V19.USD","IE00B19Z8W00.USD","IE00BLSP4239.USD","IE00B5TLWC47.USD"],"gpt_icon":0},{"id":"2479825504","title":"Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2479825504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479825504?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:28","pubTimestamp":1730230080,"startTime":"0","endTime":"0","summary":"Regained compliance without effecting a reverse stock splitTevogen Bio CEO reaffirms his commitment to preserve shareholder value WARREN, N.J., Oct.  29, 2024  (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevoge","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/29/2971173/0/en/Tevogen-Bio-Reports-Nasdaq-Listing-Compliance-as-CEO-Reaffirms-His-Commitment-in-Bridging-the-Information-Gap-About-the-Company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000KEQY171.SGD","PSQ","IE00BFSS8Q28.SGD","TQQQ","QID","IE00BDRTCR15.USD","LU2210150020.SGD","IE00B775SV38.USD","IE0004445239.USD","IE0009G5SDU7.USD","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","IE00BK4W5L77.USD","IE00B19Z9505.USD","IE00B19Z8X17.USD","IE00B5TLWC47.USD","IE00BFXG0V08.USD","SQQQ","IE00BJTD4V19.USD","BK4525","NQmain","IE00B3SWFQ91.USD","BK4504","IE00BJLML261.HKD","LU2095319765.USD","IE00BDCRKT87.USD","IE000YTNTUN2.SGD","BK4527","IE0034235303.USD","IE000ITXATA3.USD","IE00BFSS7M15.SGD","BK4503","IE00B4JS1V06.HKD","III","NDAQ","IE00BJTD4N35.SGD","IE0034235295.USD","MNQmain","IE00B7KXQ091.USD",".IXIC","QLD","IE00BJJMRY28.SGD","TVGN","IE00B19Z8W00.USD","BK4592","BK4516","LU2210149790.SGD","IE0003U64NQ7.SGD","BK4528"],"gpt_icon":1},{"id":"2479423052","title":"BRIEF-Tevogen Bio Signs LOI With Cd8 Technology To Build $50 Million R&D And Manufacturing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2479423052","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479423052?lang=en_us&edition=fundamental","pubTime":"2024-10-30 02:13","pubTimestamp":1730225621,"startTime":"0","endTime":"0","summary":"Oct 29 (Reuters) - Tevogen Bio Holdings Inc   :   * TEVOGEN BIO SIGNS LETTER OF INTENT WITH CD8 TECHNOLOGY TO BUILD UP TO A $50 MILLION RESEARCH AND DEVELOPMENT AND MANUFACTURING FACILITY; NO IMPACT ON SHAREHOLDER EQUITYFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGSX","TVGN","BK4139"],"gpt_icon":0},{"id":"2479223112","title":"Tevogen Bio Signs Letter of Intent With CD8 Technology for R&D, Manufacturing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2479223112","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479223112?lang=en_us&edition=fundamental","pubTime":"2024-10-30 01:12","pubTimestamp":1730221944,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings (TVGN) said Tuesday it has signed a letter of intent with CD8 Technology Services to build up to a $50 million facility for research and development and manufacturing.Tevogen said","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2479362762","title":"Tevogen Bio Signs Letter of Intent With Cd8 Technology to Build up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2479362762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479362762?lang=en_us&edition=fundamental","pubTime":"2024-10-30 00:43","pubTimestamp":1730220219,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nFWN3M51D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGN","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVGN","date":"2025-04-25","current":-13.530067,"percent":0.656934,"low":-87.683882,"twenty":-32.809553,"median":-22.063146,"eighty":-7.757841,"high":-2.106753,"avg":-23.042099,"sd":16.228005,"marketCap":185732367},"quantilePoints":[{"date":"2024-03-01","current":-58.029616,"twenty":-57.969868,"median":-57.58151,"eighty":-55.109463,"marketCap":1279054027},{"date":"2024-03-08","current":-55.116932,"twenty":-57.969868,"median":-57.3948,"eighty":-55.049716,"marketCap":1214854404},{"date":"2024-03-15","current":-48.544723,"twenty":-57.715942,"median":-55.116932,"eighty":-49.664986,"marketCap":1069993717},{"date":"2024-03-22","current":-31.890149,"twenty":-57.596447,"median":-52.465643,"eighty":-44.108482,"marketCap":702903564},{"date":"2024-03-28","current":-25.919148,"twenty":-57.357457,"median":-49.38492,"eighty":-32.983824,"marketCap":571294337},{"date":"2024-04-05","current":-25.392625,"twenty":-55.998205,"median":-48.543977,"eighty":-28.607629,"marketCap":559689021},{"date":"2024-04-12","current":-18.446995,"twenty":-55.146806,"median":-35.064227,"eighty":-23.267262,"marketCap":406597612},{"date":"2024-04-19","current":-15.833048,"twenty":-54.915285,"median":-32.71989,"eighty":-19.118705,"marketCap":348982566},{"date":"2024-04-26","current":-6.348156,"twenty":-53.503754,"median":-29.329228,"eighty":-17.595595,"marketCap":139922255},{"date":"2024-05-03","current":-7.365355,"twenty":-52.428301,"median":-25.919148,"eighty":-15.026459,"marketCap":162342739},{"date":"2024-05-10","current":-2.698495,"twenty":-50.822591,"median":-23.061357,"eighty":-9.708944,"marketCap":163198734},{"date":"2024-05-17","current":-2.422494,"twenty":-49.291565,"median":-20.164731,"eighty":-7.316959,"marketCap":146506832},{"date":"2024-05-24","current":-2.231961,"twenty":-48.694091,"median":-18.372311,"eighty":-2.71254,"marketCap":134983822},{"date":"2024-05-31","current":-2.106753,"twenty":-48.544425,"median":-17.961548,"eighty":-2.656034,"marketCap":127411559},{"date":"2024-06-07","current":-8.033143,"twenty":-47.558444,"median":-17.550785,"eighty":-2.656034,"marketCap":148265257},{"date":"2024-06-14","current":-7.903098,"twenty":-44.108482,"median":-15.833048,"eighty":-2.68298,"marketCap":145865070},{"date":"2024-06-21","current":-6.795171,"twenty":-36.221832,"median":-12.47226,"eighty":-2.696046,"marketCap":125416385},{"date":"2024-06-28","current":-6.570165,"twenty":-35.295748,"median":-12.322891,"eighty":-2.697026,"marketCap":121263525},{"date":"2024-07-05","current":-6.173255,"twenty":-33.757254,"median":-8.033143,"eighty":-2.703177,"marketCap":113937879},{"date":"2024-07-12","current":-6.299258,"twenty":-33.071802,"median":-7.830197,"eighty":-2.721904,"marketCap":116263481},{"date":"2024-07-15","current":-6.435162,"twenty":-32.983824,"median":-7.830197,"eighty":-2.721904,"marketCap":118771808},{"date":"2024-08-02","current":-5.57114,"twenty":-32.895846,"median":-7.830197,"eighty":-2.721904,"marketCap":102824824},{"date":"2024-08-09","current":-5.526139,"twenty":-32.222045,"median":-7.468419,"eighty":-3.563104,"marketCap":101994252},{"date":"2024-08-16","current":-20.612899,"twenty":-30.545833,"median":-7.468046,"eighty":-4.127144,"marketCap":122353801},{"date":"2024-08-23","current":-17.275162,"twenty":-29.265149,"median":-7.830197,"eighty":-4.681198,"marketCap":102541700},{"date":"2024-08-30","current":-14.308285,"twenty":-28.407028,"median":-7.866648,"eighty":-5.281333,"marketCap":84930944},{"date":"2024-09-06","current":-12.936966,"twenty":-27.171154,"median":-9.617885,"eighty":-5.454137,"marketCap":76791088},{"date":"2024-09-13","current":-14.230663,"twenty":-25.708539,"median":-12.097501,"eighty":-5.499138,"marketCap":84470197},{"date":"2024-09-20","current":-12.649478,"twenty":-24.871927,"median":-12.454498,"eighty":-5.544139,"marketCap":75084620},{"date":"2024-09-27","current":-11.784139,"twenty":-23.267262,"median":-12.36199,"eighty":-5.658262,"marketCap":69948149},{"date":"2024-10-04","current":-8.756889,"twenty":-21.942215,"median":-12.240382,"eighty":-5.887588,"marketCap":51979034},{"date":"2024-10-11","current":-9.208245,"twenty":-21.329829,"median":-12.040003,"eighty":-6.069393,"marketCap":54658190},{"date":"2024-10-18","current":-39.673363,"twenty":-24.871927,"median":-12.127687,"eighty":-6.141394,"marketCap":235492672},{"date":"2024-10-25","current":-73.596963,"twenty":-29.393307,"median":-12.327491,"eighty":-6.173255,"marketCap":436855971},{"date":"2024-10-31","current":-70.722082,"twenty":-31.779361,"median":-12.436737,"eighty":-6.180635,"marketCap":419791285},{"date":"2024-11-08","current":-32.773648,"twenty":-33.757254,"median":-12.633666,"eighty":-6.224556,"marketCap":194537424},{"date":"2024-11-15","current":-42.548244,"twenty":-38.983392,"median":-12.936966,"eighty":-6.285578,"marketCap":252557358},{"date":"2024-11-22","current":-36.270609,"twenty":-39.155884,"median":-13.187081,"eighty":-6.299438,"marketCap":287084045},{"date":"2024-11-29","current":-28.972255,"twenty":-38.235922,"median":-13.602501,"eighty":-6.300158,"marketCap":229317133},{"date":"2024-12-06","current":-23.222036,"twenty":-37.373458,"median":-13.816575,"eighty":-6.348156,"marketCap":183803809},{"date":"2024-12-13","current":-22.337387,"twenty":-36.270609,"median":-14.269474,"eighty":-6.435162,"marketCap":176801759},{"date":"2024-12-20","current":-21.33331,"twenty":-36.221832,"median":-15.004006,"eighty":-6.508963,"marketCap":168854432},{"date":"2024-12-27","current":-23.222036,"twenty":-35.303209,"median":-15.833048,"eighty":-6.557925,"marketCap":183803809},{"date":"2025-01-03","current":-23.443198,"twenty":-34.373394,"median":-17.065337,"eighty":-6.580965,"marketCap":185554321},{"date":"2025-01-10","current":-28.52993,"twenty":-33.790638,"median":-17.550785,"eighty":-6.670967,"marketCap":225816108},{"date":"2025-01-17","current":-26.760632,"twenty":-33.439732,"median":-17.684618,"eighty":-6.873653,"marketCap":211812008},{"date":"2025-01-24","current":-30.52039,"twenty":-33.171426,"median":-18.032197,"eighty":-7.005548,"marketCap":241570720},{"date":"2025-01-31","current":-29.635741,"twenty":-33.528197,"median":-18.446995,"eighty":-7.075423,"marketCap":234568670},{"date":"2025-02-07","current":-31.405039,"twenty":-33.171426,"median":-19.295444,"eighty":-7.138439,"marketCap":248572770},{"date":"2025-02-14","current":-34.501311,"twenty":-33.892862,"median":-20.164731,"eighty":-7.192457,"marketCap":273079945},{"date":"2025-02-21","current":-34.280148,"twenty":-34.280148,"median":-20.612899,"eighty":-7.244366,"marketCap":271329432},{"date":"2025-02-28","current":-27.645281,"twenty":-34.280148,"median":-21.570546,"eighty":-7.365355,"marketCap":218814058},{"date":"2025-03-07","current":-24.327847,"twenty":-34.058986,"median":-22.031836,"eighty":-7.370735,"marketCap":192556371},{"date":"2025-03-14","current":-24.54901,"twenty":-33.906622,"median":-22.226806,"eighty":-7.443187,"marketCap":194306884},{"date":"2025-03-21","current":-25.875983,"twenty":-33.837824,"median":-22.558549,"eighty":-7.452187,"marketCap":204809958},{"date":"2025-03-28","current":-26.53947,"twenty":-33.616662,"median":-23.000874,"eighty":-7.454567,"marketCap":210061496},{"date":"2025-04-04","current":-13.396106,"twenty":-33.174337,"median":-23.222036,"eighty":-7.467672,"marketCap":183893433},{"date":"2025-04-11","current":-13.396106,"twenty":-33.15978,"median":-22.669131,"eighty":-7.468419,"marketCap":183893433},{"date":"2025-04-17","current":-13.664028,"twenty":-32.994496,"median":-22.447968,"eighty":-7.468419,"marketCap":187571301},{"date":"2025-04-25","current":-13.530067,"twenty":-32.809553,"median":-22.063146,"eighty":-7.757841,"marketCap":185732367}],"updateTime":1745689271925}}}